From Near-Term FDA Nod Unlikely For Duchenne Drug After Negative Vote:

Debra Miller at FDA April 2016
Debra Miller at FDA April 2016

CureDuchenne CEO Debra Miller speaks at an FDA advisory panel for eteplirsen.